<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03288636</url>
  </required_header>
  <id_info>
    <org_study_id>ASC-ASC16-I-CTP-02</org_study_id>
    <nct_id>NCT03288636</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China</brief_title>
  <official_title>A Phase I Study to Assess the Pharmacokinetics and Safety of Single Dose of Ravidasvir and Danoprevir/r and Repeated Doses of Ravidasvir in Combination With Danoprevir/r in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascletis Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascletis Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the Pharmacokinetics and Safety of single dose of
      Ravidasvir and Danoprevir/r and repeated doses of Ravidasvir in combination with Danoprevir/r
      in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2017</start_date>
  <completion_date type="Actual">October 28, 2017</completion_date>
  <primary_completion_date type="Actual">September 14, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>40 days</time_frame>
    <description>Incidence of adverse events</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>HCV</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PKGroup:
Ravidasvir + Danoprevir/ Ritonavir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Group:
Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danoprevir</intervention_name>
    <description>Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ravidasvir</intervention_name>
    <description>Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>ASC16(RDV)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18-45 years old;

          -  Male body weight not less than 50kg; Female body weight not less than 45kg; BMI in the
             range of 19~28kg/m2

          -  Healthy men or women based on history, physical examination, laboratory examination
             and ECG.

          -  Female subjects should be surgically sterilized (bilateral tubal ligation, bilateral
             ovariectomy or hysterectomy); or are willing to use at least one of the following
             contraceptive methods within 30 days of the first administration of the study drug
             until the last administration: I Male partner vas deferens ligation; II. Non-hormonal
             contraceptive methods: intrauterine contraceptives, condoms, contraceptive sponges,
             septa, vaginal ring containing sizing gel or cream.

          -  Male subjects should be surgically sterilized; or are willing to use at least one of
             the following contraceptive methods within 30 days from the first administration of
             the study to the last administration: I. Female partners abstinence during the study
             period (including no donation): II. Compounds use hormonal contraceptives (oral,
             vaginal, parenteral or transdermal); III. Subjects and / or their female partners use
             non-hormonal contraceptive methods: condoms, contraceptive sponges, membranes,
             intrauterine devices, Fine gel or cream of the vaginal ring.

          -  If female, the pregnancy test result should be negative during the screening period.

          -  Voluntary to sign the informed consent.

        Exclusion Criteria:

          -  History or presence of cardiovascular disease, respiratory disease, endocrine and
             metabolic system disease, urinary system, digestive system, hematological system
             diseases, nervous system or Psychiatric diseases, and acute or chronic infectious
             disease and malignant tumor.

          -  A history of drug or food allergy.

          -  Positive test in any of the HBsAg、HCV Ab、HIV Ab and Syphilis Ab.

          -  Any of the AST、ALT、ALP、TBIL and DBIL exceed the upper limits of normal, or other
             laboratory test results exceeding the normal range and judged by the investigator to
             be clinically significant.

          -  History of gastrointestinal surgery, trunk vagotomy, intestinal excision or any other
             surgeries that could disturb gastrointestinal motility and PH absorption.

          -  Female who were during pregnancy, breastfeeding, period and unwilling to take reliable
             birth control method.

          -  Female partners were fertile and unwilling to take reliable contraceptive measures.

          -  Others as specified in the detailed protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The first hospital of Zhejiang province</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2017</study_first_submitted>
  <study_first_submitted_qc>September 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2017</study_first_posted>
  <last_update_submitted>January 14, 2018</last_update_submitted>
  <last_update_submitted_qc>January 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lactams</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

